Regulatory Strategy
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…
-
MHRA Proposes Indefinite Recognition of CE Marked Medical Devices in Great Britain
You did not build your company to spend its best energy navigating paperwork. You built it to move something that matters, a device, an idea, a breakthrough, from concept to clinic and from prototype to patient. The ambition has always been clear: to get life-saving products into the hands of clinicians efficiently, without unnecessary friction…
Harun Rabbani 